« Back
Home /
KTX-951

KTX-951

Item no.	HY-148290-10mg
Manufacturer	MedChem Express
CASRN	2573298-36-7
Amount	10 mg
Quantity options	10mM/1mL 10 mg 1 ea 1 mg 25 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.03
Formula	C46H52F2N8O6
Citations	[1]Walker D H, et al. Degraders targeting both IRAK4 and IMiD substrates show combinatorial effects leading to broader activity with durable and complete regressions in MYD88 mutant lymphoma xenografts in vivo. Cancer Research, 2020, 80(16_Supplement): 5222-5222.
Smiles	FC(F)(C)C1=CC=CC(C(NC(C(OC)=CC2=N3)=CC2=CN3[C@H]4CC[C@@H](CC4)CN5CCC6(CC(CCNC7=C(C8=O)C(C(N8C(C(N9)=O)CCC9=O)=O)=CC=C7)C6)CC5)=O)=N1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Available
Product Description	KTX-951 is a PROTAC targeting IRAK4 degradation (DC50=18 nM). KTX-951 (10 mg/kg) shows the oral bioavailability (F%) of 22% in a rat model. KTX-951 has good anticancer potential[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	850.95
Clinical Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	DMSO : 50 mg/mL (ultrasonic)
Target	IRAK; PROTACs
Manufacturers Target	IRAK; PROTACs
Manufacturers Pathway	Immunology/Inflammation; PROTAC
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 10 mg

available

Request delivery time